摘要
目的探讨氯氮平合并托吡酯维持治疗精神分裂症的疗效及安全性。方法共纳入72例稳定服用治疗剂量或维持剂量的氯氮平患者,随机分为两组,1组合并托吡酯治疗(研究组),另1组单用氯氮平治疗(对照组)。观察治疗6个月,对比两组间治疗前后PANSS量表总分、各分量表分的减分值以及UKU不良反应量表评分。结果研究组治疗6个月后阴性量表分、一般精神病量表分及PANSS量表总分减分均较对照组差异有统计学意义(t=2.382,2.321,3.077;P均<0.05)。两组间UKU不良反应量表评分无差异(t=1.463,P>0.05)。结论氯氮平合并托吡酯长期维持治疗能有效缓解精神分裂症患者的症状,不增加不良反应。
Objective To explore the efficacy and safety of topiramate combined with clozapine in the treatment of schizophrenia. Methods A total of 72 cases of stable therapeutic dose or maintenance dose of clozapine were randomly divided into study group （topiramate combined with clozapine）and control group（clozapine alone）. The two groups were observed for 6 months. The study group was compared with the control group of changes of PANSS total scores,each subscale scores and UKU side effect rating scale scores after 6 months treatment. Results The two groups after treatment were significantly lower than before treatment in posi- tive symptoms subseale scores,negative symptoms subscale scores,general psychiatric subscale scores and total score （t = 13. 081, 13. 239,28. 492,25. 533,8,769,8. 310,20. 494,17. 169 ; P〈0. 001）. Negative symptoms subscale scores ,general psychiatric scores and total scores of the study group were decreased significantly than that of the control group（t= 2. 382,2. 321,3. 077 ;P〈0.05）. There was no difference in UKU side effect rating scale scores between two groups（t= 1. 463,P〉0.05）. Conclusion Topiramate combined with clozapine can alleviate symptoms of schizophrenia significantly,without increasing adverse events.
出处
《中国健康心理学杂志》
2012年第7期964-965,共2页
China Journal of Health Psychology
